Phase II Study of Thalidomide for Patients with Metastatic Renal Cell Carcinoma (MRCC) Progressing After Interleukin-2 (IL-2)-Based Therapy (Rx). - Li,Z.; Amato,R.; Papandreou,C.; Pagliaro,L.; Kim,J.; Millikan,R.; Loggins-Coffman,J.; Perez,C.; Logothetis,C.; Daliani,D. (ASCO Annual Meeting, 2001)